Skip to main content

BioCommerce Week s Index to the Diversified Molecular Biology Tools Companies: Dec 2, 2004

 

Bruker Shares Continue to Be Buoyed by Laukien’s 200,000 Share Purchase

The share price of Bruker BioScience improved 6 percent over a six-day coverage period for the BioCommerce Week Index, closing Monday at $33.92, continuing a gain ignited largely by the insider purchase of 200,000 Bruker shares by CEO Frank Laukien.

Over the last two weeks, Bruker’s share price has improved 25 percent and led nine companies among the 15 select molecular biology tools companies tracked in the index during the six-day tracking period ending Tuesday. The usual five-day period was lengthened because of the Thanksgiving holiday in the US.

Beckman Coulter followed Bruker’s gain with a 3 percent improvement on the week, closing at $65.46 Tuesday, compared to $63.74 for the previous week. PerkinElmer shares were up 2.6 percent, closing at $21.33 Tuesday, compared to $20.80 last week. Sigma-Aldrich improved to $59.73 over the previous week’s $58.68, a 1.8-percent increase. Thermo closed at $30.25, up 1 percent over last week’s $29.91 price. Stratagene closed at $6.86, up almost 1 percent over last week’s $6.80, while Waters and Bio-Rad improved a fraction.

Harvard Bioscience was down 9 percent, closing at $3.96 from $4.34 a week ago to lead six BCW companies whose shares finished the week down. GE dropped 2 percent to $35.36 from last week’s $36.09, and Invitrogen fell 1.7 percent to $60.50 from $62.54. Other losers included Agilent, Molecular Devices, and Applied Biosystems.

While Agilent closed at $22.89, down from the previous week’s $23.08, the company share price has gained 14 percent since the BCW index debuted on Sept. 9.

Overall, the index finished at $34.04, an 8-percent improvement and a fifth consecutive week of gains.

For the week, the index outperformed the major market indexes. The Dow fell just under 1 percent for the five-day period while the S&P 500 fell a half percent and the Nasdaq index was up approximately one quarter percent. The Amex Biotech index was down a fraction of a percent while the Amex Pharma Index improved a quarter of a percent.

File Attachments
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.